Do you want to read an article? Please log in or register.
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Glycemic Control
Related content
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
BMJ
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM
doi: 10.1136/bmj.m4573
COMMENTED
Diabetes - General
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus
Ann Intern Med.
Roglic G, Norris SL
doi: 10.7326/M18-1149.
Type 2 Diabetes
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial
Diabetes Obes Metab.
Del Prato S, Frias JP, Blonde L, Aroda VR, Shehadeh N, Saremi A, Dex T, Niemoeller E, Souhami E, Liu M, Rosenstock J
doi: 10.1111/dom.14068.
COMMENTED
Type 2 Diabetes
Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Apostolos Tsapas, Bekiari E
doi: 10.1111/dom.14108.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis
JAMA.
Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K
doi: 10.1001/jama.2018.3024.
RECOMMENDED
Type 2 Diabetes
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Lancet Diabetes Endocrinol.
Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A
doi: 10.1016/S2213-8587(19)30066-X.
Type 2 Diabetes
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Diabetes Care.
Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR
doi: 10.2337/dc19-1357.
Type 2 Diabetes
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
Diabet Med.
Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ
doi: 10.1111/dme.
COMMENTED
Type 2 Diabetes
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A
doi: 10.1016/S0140-6736(18)32260-8.